StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1466.HK$0.55+5.77%
Fair $0.55+0.0%

1466.HK

Baijin Life Science Holdings Limited

Consumer Cyclical / Luxury GoodsHKSE

$0.55

+0.03 (+5.77%)

Fairly Valued+0.0%Fair Value $0.55Fund rank 26/100 · Data gapFallback financials|
SA 32/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-21.5M · quality 50.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

32/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is -0.2%, below the 5% threshold
Thesis & Journal · 1466.HKLocal privado en este navegador · Baijin Life Science Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$513M

P/E

55.0x

↑

EV/EBITDA

69.3x

↑

ROE

-0.2%

↓

Gross Margin

31.0%

↑

Debt/Equity

0.72

↑
52-Week Range$1
$0$1

TradingView lightweight chart

1466.HK price, volumen y niveles de valoración

Último $0.550Periodo -62.9%
Fair value: $0.550

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+29.3%

FCF CAGR

—

FCF margin

-24.3%

FCF / Net income

104.34x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $135.6M · net income $-316000.0 · FCF $-33.0M

2022-FY → 2025-FY

Gross margin

31.0%+13.4% pts

Operating margin

4.6%+21.1% pts

Net margin

-0.2%+24.4% pts

FCF margin

-24.3%-26.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$135.6M$135.6M$53.7M$86.9M$62.6M
Net Income$-316000.00$-316000.00$-7.4M$8.7M$-15.5M
EBITDA$6.3M$6.3M$-6.3M$11.1M$-9.7M
EPS-0.00-0.00-0.010.01-0.04
Gross Margin31.0%31.0%33.7%9.0%17.5%
Operating Margin4.6%4.6%-18.7%12.7%-16.5%
Net Margin-0.2%-0.2%-13.9%10.0%-24.7%
Balance Sheet
Debt/Equity0.720.720.530.040.89
Current Ratio4.214.21———
Cash Flow
Free Cash Flow$-33.0M$-33.0M$-6.6M$-21.5M$1.1M
Returns
ROE-0.2%-0.2%-7.7%11.1%-43.1%
Valuation
P/E55.0055.00—69.00—
EV/EBITDA69.2669.26—33.95—
P/B2.742.744.155.321.19
Growth & Yield
Revenue Growth152.5%152.5%-38.2%38.7%—
EPS Growth95.0%95.0%-200.0%125.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -19.1%

Total return

-19.1%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → -0.00

Residual

-19.1%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-19.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.